Ravulizumab in Patients with Generalized Myasthenia Gravis (gMG) from Japan: Real-world Outcomes (P7-11.023)
The ravulizumab postmarketing surveillance (PMS) is ongoing to assess its real-world safety and effectiveness in adult patients with gMG in Japan, in accordance with regional guidelines. Here we report the first interim analysis from the ravulizumab gMG PMS.
Authors
- Akiyuki Uzawa (ORCID: https://orcid.org/0000-0001-9252-1863)
- Masaki Okuda
- Kimiaki Utsugisawa (ORCID: https://orcid.org/0000-0001-9373-8167)
- Mitsuru Watanabe (ORCID: https://orcid.org/0000-0003-0831-623X)
- Kenzo Sakurai (ORCID: https://orcid.org/0000-0002-9516-6753)
- Shigeaki Suzuki (ORCID: https://orcid.org/0000-0003-4388-4574)
- Hiroyuki Murai (ORCID: https://orcid.org/0000-0003-1612-1440)
- Masanori Takahashi (ORCID: https://orcid.org/0000-0002-5513-5012)
- Benjamin J. Yungher
- Takanori Yamamoto (ORCID: https://orcid.org/0000-0002-5835-7120)
Institutions
- Kyushu University (JP)
- Chiba University (JP)
- St. Marianna University School of Medicine (JP)
- Keio University (JP)
- AstraZeneca (Brazil) (BR)
- National Hospital Organization Hanamaki Hospital (JP)
- Alexion Pharma (Switzerland) (CH)
- International University of Health and Welfare (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208758
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00